·Scientific Research
Current position:
英文主页
>
Scientific Research
Research Field
-
1.andrology 2.prostatic cancer 3.urolithiasis
Paper Publications
MORE+- [1] 1. Li H, Chen LP, Yang J, Li MC, Chen RB, Lan RZ, Wang SG, Liu JH, Wang T.Predictive value of FSH, testicular volume, and histopathological findings for the sperm retrieval rate of microdissection TESE in nonobstructive azoospermia: a meta-analysis. Asian J Androl. 2017 Mar 24.[Epub ahead of print]
- [2] 2. Wang T, Cai Y, Song W, Chen R, Hu D, Ye J, Liu L, Peng W, Zhang J, Wang S, Yang W, Liu J, Ding Y.Ethyl Acetate Extracts of Semen Impatientis Inhibit Proliferation and Induce Apoptosis of Human Prostate Cancer Cell Lines through AKT/ERK Pathways.Biomed Res Int. 2017;2017:1243515. IF=2.476
- [3] 3. Chen Z, Liu Q, Chen R, Liu Z, Li M, Ling Q, Wu L, Yang J, Liu X, Wang T, Hu Z, Guo X, Wang S, Yang W, Liu J.Clinical analysis of small cell carcinoma of the bladder in Chinese: nine case reports and literature reviews.World J Surg Oncol. 2017 Jan 26;15(1):33. IF=1.600
- [4] 4. Liu Z, Jiang H, Yang J, Wang T, Ding Y, Liu J, Wang S, Ye Z.Analysis of altered microRNA expression profiles in the kidney tissues of ethylene glycol-induced hyperoxaluric rats. Mol Med Rep. 2016; 14(5):4650-58. (*As corresponding author) IF=1.692
- [5] 5. Wang T, Song W, Chen Y, Chen R, Liu Z, Wu L, Li M, Yang J, Wang L, Liu J, Ye Z, Wang C, Chen K. Flightless I Homolog Represses Prostate Cancer Progression through Targeting Androgen Receptor Signaling.Clin Cancer Res. 2016 ;22(6):1531-44. IF=9.619
Patents
- No Content
Published Books
- No Content
Research Projects
MORE+- [1] 2019.01.01-2022.12.31:"B7-H4/AR正反馈调节及介导的免疫逃避在前列腺癌去势抵抗中的机制研究(No:8187111154)"国家自然科学基金课题。83.8万
- [2] 2015.1~2018.12:“AR/miRNA-190/YB-1负反馈循环机制及对前列腺癌抑制作用的生物学研究(No: 81472405)”国家自然科学基金课题,80.0万,课题组排名第二。
- [3] 2016.1~2019.12:“DNMT1/CAMK2N1反馈调节及其介导的甲基化修饰在前列腺癌去势抵抗中的作用机制研究(No: 81572539)”国家自然科学基金课题,78.0万,课题负责人。
- [4] 2004.9~2006.9: “电子射精仪电刺激诱导射精治疗不射精症”,2004年同济医院新业务新技术基金课题,2.0万,课题组排名第二。
- [5] 2005.6~2006.7:“评价达泊西汀在治疗早泄中的疗效与安全性的随机、双盲、安慰剂对照、国际多中心临床试验”,(方案号:R096769-PRE-3003),课题组排名第二。